Delineation of recurrent glioblastoma by whole brain spectroscopic magnetic resonance imaging.
Delineation of recurrent glioblastoma by whole brain spectroscopic magnetic resonance imaging.
复制标题
DOI：
10.1186/s13014-023-02219-2
复制
发表时间：
2023-02-22
期刊：
影响因子：
--
通讯作者：
Mellon EA
中科院分区：
文献类型：
--
作者：
Bell JB;Jin W;Goryawala MZ;Azzam GA;Abramowitz MC;Diwanji T;Ivan ME;Del Pilar Guillermo Prieto Eibl M;de la Fuente MI;Mellon EA
胶质母细胞瘤（GBM）的细胞与全脑光谱MRI（SMRI）相关，生成了相对的胆碱与N-乙酰基天冬氨酸比率（RCHONAA）映射，在复发性GBM（RGBM）中。
在一项前瞻性研究中，RGBM患者进行了SMRI。高度（ADC）地图和灌注相对脑血体积（RCBV）。
RCHONAA> 2（平均27.6cc，6.6-79.1cc）与其他成像模态不同（p≤0.05）是平均T1PC量为10.7cc（范围1.2-31.4cc）。 T2/FLAIR量（平均111.7cc，范围19.0-232.7 cc比其他模态大得多REE和RE-RT患者的总生存期为6.5，分别为7.1个月。
RGBM的处理可以通过SMRI进行优化，而失败模式表明，在SMRI剥离体积中的剂量升级有益。
Glioblastoma (GBM) cellularity correlates with whole brain spectroscopic MRI (sMRI) generated relative choline to N-Acetyl-Aspartate ratio (rChoNAA) mapping. In recurrent GBM (rGBM), tumor volume (TV) delineation is challenging and rChoNAA maps may assist with re-RT targeting. Fourteen rGBM patients underwent sMRI in a prospective study. Whole brain sMRI was performed to generate rChoNAA maps. TVs were delineated by the union of rChoNAA ratio over 2 (rChoNAA > 2) on sMRI and T1PC. rChoNAA > 2 volumes were compared with multiparametric MRI sequences including T1PC, T2/FLAIR, diffusion-restriction on apparent diffusion coefficient (ADC) maps, and perfusion relative cerebral blood volume (rCBV). rChoNAA > 2 (mean 27.6 cc, range 6.6–79.1 cc) was different from other imaging modalities (P ≤ 0.05). Mean T1PC volumes were 10.7 cc (range 1.2–31.4 cc). The mean non-overlapping volume of rChoNAA > 2 and T1PC was 29.2 cm3. rChoNAA > 2 was 287% larger (range 23% smaller–873% larger) than T1PC. T2/FLAIR volumes (mean 111.7 cc, range 19.0–232.7 cc) were much larger than other modalities. rCBV volumes (mean 6.2 cc, range 0.2–19.1 cc) and ADC volumes were tiny (mean 0.8 cc, range 0–3.7 cc). Eight in-field failures were observed. Three patients failed outside T1PC but within rChoNAA > 2. No grade 3 toxicities attributable to re-RT were observed. Median progression-free and overall survival for re-RT patients were 6.5 and 7.1 months, respectively. Treatment of rGBM may be optimized by sMRI, and failure patterns suggest benefit for dose-escalation within sMRI-delineated volumes. Dose-escalation and radiologic-pathologic studies are underway to confirm the utility of sMRI in rGBM.
登录
查看更多内容
DOI：
10.1016/j.ijrobp.2009.12.061
发表时间：
2011-04-01
影响因子：
7
作者：
Levin, Victor A.;Bidaut, Luc;Hou, Ping;Kumar, Ashok J.;Wefel, Jeffrey S.;Bekele, B. Nebiyou;Prabhu, Sujit;Loghin, Monica;Gilbert, Mark R.;Jackson, Edward F.
通讯作者：
Jackson, Edward F.
影响因子：
15.9
作者：
Cordova, James S.;Shu, Hui-Kuo G.;Shim, Hyunsuk
通讯作者：
Shim, Hyunsuk
DOI：
10.1186/s13014-021-01767-9
发表时间：
2021-02-18
期刊：
Radiation oncology (London, England)
影响因子：
--
作者：
Minniti G;Niyazi M;Alongi F;Navarria P;Belka C
通讯作者：
Belka C
影响因子：
2.5
作者：
Ebel, A;Maudsley, AA
通讯作者：
Maudsley, AA
影响因子：
1.9
作者：
Kim, Michelle M.;Parmar, Hemant A.;Cao, Yue
通讯作者：
Cao, Yue